Advertisement
Advertisement
August 18, 2022
BD Launches PREVISION FIH Trial of a Peripheral Sirolimus DCB
August 18, 2022—BD (Becton, Dickinson and Company) announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). The company initiated this trial to determine the viability of sirolimus as a future treatment option for patients with peripheral artery disease (PAD).
According to the company, the PREVISION trial is a prospective, multicenter, single-arm, nonrandomized study designed to evaluate the safety of the BD sirolimus DCB in the treatment of PAD in the femoropopliteal arteries. PREVISION is being conducted across multiple sites in Australia, New Zealand, and Singapore. The trial will enroll and follow up on approximately 50 patients over the coming months.
The first patient was successfully treated by Andrew Holden, MD, who is the study’s Principal Investigator at Auckland City Hospital in Auckland, New Zealand.
“It is an honor to enroll the first patient in the PREVISION study,” commented Dr. Holden in the company’s press release. “The burden of PAD continues to impact patients and challenge physicians around the globe. A continued focus on developing next-generation technology is important for the patients suffering from PAD.”
Advertisement
Advertisement
